Skip to main content
David Strayer, MD, Oncology, Philadelphia, PA

DavidRodneyStrayerMD

Oncology Philadelphia, PA

Physician

Are you Dr. Strayer?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 1 invite waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. David Strayer, MD is an oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and California.

Education & Training

  • University of California, Davis, School of Medicine
    University of California, Davis, School of MedicineClass of 1972

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1980 - 2024
  • CA State Medical License
    CA State Medical License 1973 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Press Mentions

  • AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue, Combination and Innovative Therapies for Pancreatic Cancer
    AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue, Combination and Innovative Therapies for Pancreatic CancerMarch 29th, 2022
  • AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer
    AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic CancerMarch 8th, 2022
  • AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer
    AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian CancerJanuary 24th, 2022